Dupuytren's disease: history, diagnosis, and treatment.
OBJECTIVE
After studying this article, the participant should be able to: 1. Describe the clinical features of the disease. 2. Describe the pathoanatomical structures in Dupuytren's disease. 3. Outline the various factors associated with Dupuytren's disease. 4. Describe the modalities for surgical and nonsurgical treatment of the condition. 5. Outline recent biomolecular knowledge about the basis of Dupuytren's disease.


CONCLUSIONS
Dupuytren's disease is characterized by nodule formation and contracture of the palmar fascia, resulting in flexion deformity of the fingers and loss of hand function. The authors review the historical background, clinical features, and current therapy of Dupuytren's disease; preview treatment innovations; and present molecular data related to Dupuytren's disease. These new findings may improve screening for Dupuytren's disease and provide a better understanding of the disease's pathogenesis.
Shaw
Robert B
RB
Stanford and Palo Alto, Calif. From the Division of Plastic and Reconstructive Surgery, Stanford University Medical Center, and the Veterans Affairs Palo Alto Health Care System.
Chong
Alphonsus K S
AKS
Zhang
Andrew
A
Hentz
Vincent R
VR
Chang
James
J
D004387:Dupuytren Contracture / Q000175:diagnosis* / Q000601:surgery* / Q000628:therapy; D006801:Humans; D019651:Plastic Surgery Procedures / Q000379:methods
Elliot, D. Pre-1900 literature on Dupuytren’s disease. Hand Clin. 15: 175, 1999.
Thurston, A. Dupuytren’s disease or Cooper’s contracture? Kenneth Fitzpatrick Russell Memorial Lecture. Aust. N. Z. J. Surg. 73: 529, 2003.
Dupuytren, G. De la rétraction des doigts par suite d’une affection de l’aponévrose palmaire—description de la maladie—operation chirurgicale qui convient dans ce cas. Compte rendu de la clinique chirurgicale de l’Hôtel Dieu par MM, les docteurs Alexandre Paillard et Marx. J. Universel Hebdomodaire Med. Chir. Pratiques Inst. Med. 5: 349, 1831.
Dupuytren, G. Permanent retraction of the fingers produced by an affection of the palmar fascia. Lancet 2: 222, 1834.
Goyrand, G. Nouvelles recherches sur la rétraction permanente des doigts. Mem. Acad. R. Med. 3: 489, 1833.
Sanson, J., and Breschet, G. Critique on Goyrand. Mem. Acad. R. Med. 4: 496, 1833.
Goyrand, G. De la rétraction permanente des doigts. Gaz. Med. Paris 2s: 481, 1835.
Ling, R. S. The genetic factor in Dupuytren’s disease. J. Bone Joint Surg. (Br.) 45: 709, 1963.
Wilbrand, S., Ekbom, A., and Gerdin, B. The sex ratio and rate of reoperation for Dupuytren’s contracture in men and women. J. Hand Surg. (Br.) 24: 456, 1999.
Mikkelsen, O. A. The prevalence of Dupuytren’s disease in Norway: A study in a representative population sample of the municipality of Haugesund. Acta Chir. Scand. 138: 695, 1972.
Ross, D. C. Epidemiology of Dupuytren’s disease. Hand Clin. 15: 53, 1999.
Hueston, J. T. Overview of etiology and pathology. In J. T. Hueston and R. Tubiana (Eds.), Dupuytren’s Disease. Edinburgh: Churchill Livingstone, 1985.
Mitra, A., and Goldstein, R. Y. Dupuytren’s contracture in the black population: A review. Ann. Plast. Surg. 32: 619, 1994.
Egawa, T., Senrui, H., and Horiki, A. Epidemiology of the Oriental patient. In R. M. McFarlane, D. A. McGrouther, and M. Flint (Eds.), Dupuytren’s Disease Biology and Treatment. Edinburgh: Churchill Livingstone, 1990. Pp. 239–245.
McFarlane, R. M. Dupuytren’s disease: Relation to work and injury. J. Hand Surg. (Am.) 16: 775, 1991.
Skoog, T. Dupuytren’s contracture. Postgrad. Med. 21: 91, 1957.
Burge, P., Hoy, G., Regan, P., et al. Smoking, alcohol and the risk of Dupuytren’s contracture. J. Bone Joint Surg. (Br.) 79: 206, 1997.
Noble, J., Arafa, M., Royle, S. G., et al. The association between alcohol, hepatic pathology and Dupuytren’s disease. J. Hand Surg. (Br.) 17: 71, 1992.
Critchley, E. M., Vakil, S. D., Hayward, H. W., et al. Dupuytren’s disease in epilepsy: Result of prolonged administration of anticonvulsants. J. Neurol. Neurosurg. Psychiatry 39: 498, 1976.
Renard, E., Jacques, D., Chammas, M., et al. Increased prevalence of soft tissue hand lesions in type 1 and type 2 diabetes mellitus: Various entities and associated significance. Diabete Metab. 20: 513, 1994.
Arafa, M., Steingold, R. F., and Noble, J. The incidence of Dupuytren’s disease in patients with rheumatoid arthritis. J. Hand Surg. (Br.) 9: 165, 1984.
Rayan, G. M. Clinical presentation and types of Dupuytren’s disease. Hand Clin. 15: 87, 1999.
Garrod, J. Concerning pads upon the finger joints and their clinical relationships. B.M.J. 2: 8, 1904.
Caroli, A., Zanasi, S., Marcuzzi, A., et al. Epidemiological and structural findings supporting the fibromatous origin of dorsal knuckle pads. J. Hand Surg. (Br.) 16: 258, 1991.
Classen, D. A., and Hurst, L. N. Plantar fibromatosis and bilateral flexion contractures: A review of the literature. Ann. Plast. Surg. 28: 475, 1992.
Strickland, J. W., and Leibovic, S. J. Anatomy and pathogenesis of the digital cords and nodules. Hand Clin. 7: 645, 1991.
Rayan, G. M. Palmar fascial complex anatomy and pathology in Dupuytren’s disease. Hand Clin. 15: 73, 1999.
Short, W. H., and Watson, H. K. Prediction of the spiral nerve in Dupuytren’s contracture. J. Hand Surg. (Am.) 7: 84, 1982.
Bruner, J. M. The zigzag volar-digital incision for flexor-tendon surgery. Plast. Reconstr. Surg. 40: 571, 1967.
McCash, C. R. The open palm technique in Dupuytren’s contracture. Br. J. Plast. Surg. 17: 271, 1964.
Hueston, J. T. ‘Firebreak’ grafts in Dupuytren’s contracture. Aust. N. Z. J. Surg. 54: 277, 1984.
Hueston, J. T. Dermofasciectomy for Dupuytren’s disease. Bull. Hosp. Jt. Dis. Orthop. Inst. 44: 224, 1984.
Rowley D. I. Couch, M., Chesney, R. B., et al. Assessment of percutaneous fasciotomy in the management of Dupuytren’s contracture. J. Hand Surg. (Br.) 9: 163, 1984.
Rodrigo, J. J., Niebauer, J. J., Brown, R. L., et al. Treatment of Dupuytren’s contracture: Long-term results after fasciotomy and fascial excision. J. Bone Joint Surg. (Am.) 58: 380, 1976.
Hueston, J. T. Limited fasciectomy for Dupuytren’s contracture. Plast. Reconstr. Surg. 27: 569, 1961.
McIndoe, A., and Beare, R. L. The surgical management of Dupuytren’s contracture. Am. J. Surg. 95: 197, 1958.
McFarlane, R. M. Patterns of the diseased fascia in the fingers in Dupuytren’s contracture: Displacement of the neurovascular bundle. Plast. Reconstr. Surg. 54: 31, 1974.
Forgon, M., and Farkas, G. Results of surgical treatment of Dupuytren’s contracture (in German). Handchir. Mikrochir. Plast. Chir. 20: 279, 1988.
Tonkin, M. A., Burke, F. D., and Varian, J. P. Dupuytren’s contracture: A comparative study of fasciectomy and dermofasciectomy in one hundred patients. J. Hand Surg. (Br.) 9: 156, 1984.
Foucher, G., Medina, J., and Navarro, R. Percutaneous needle aponeurotomy: Complications and results (in French). Chir. Main 20: 206, 2001.
Bryan, A. S., and Ghorbal, M. S. The long-term results of closed palmar fasciotomy in the management of Dupuytren’s contracture. J. Hand Surg. (Br.) 13: 254, 1988.
McFarlane, R. M., and Botz, J. S. The results of treatment. In R. M. McFarlane, D. A. McGrouther, and M. Flint (Eds.), Dupuytren’s Disease Biology and Treatment. Edinburgh: Churchill Livingstone, 1990. Pp. 387–412.
Howard, L. D., Jr. Dupuytren’s contracture: A guide for management. Clin. Orthop. 15: 118, 1959.
Zemel, N. P. Dupuytren’s contracture in women. Hand Clin. 7: 707, 1991.
Pan, D., Watson, H. K., Swigart, C., et al. Microarray gene analysis and expression profiles of Dupuytren’s contracture. Ann. Plast. Surg. 50: 618, 2003.
Lee, L. C., Zhang, A. Y., Chong, A. K., et al. Expression of a novel gene, MafB, in Dupuytren’s disease. J. Hand Surg. (Am.) 31: 211, 2006.
Kuhn, M. A., Wang, X., Payne, W. G., et al. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in Dupuytren’s affected palmar fascia. J. Surg. Res. 103: 146, 2002.
Kataoka, K., Fujiwara, K. T., Noda, M., et al. MafB, a new Maf family transcription activator that can associate with Maf and Fos but not with Jun. Mol. Cell. Biol. 14: 7581, 1994.
Akman, H. O., Zhang, H., Siddiqui, M. A., et al. Response to hypoxia involves transforming growth factor-beta2 and Smad proteins in human endothelial cells. Blood 98: 3324, 2001.
Alory, C., and Balch, W. E. Molecular evolution of the Rab-escort-protein/guanine-nucleotide-dissociation-inhibitor superfamily. Mol. Biol. Cell 14: 3857, 2003.
Barradas, M., Gonos, E. S., Zebedee, Z., et al. Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp. Cell Res. 273: 127, 2002.
Cao, Y., Zhao, Z., Gruszczynska-Biegala, J., et al. Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro. Mol. Cell. Biol. 23: 6725, 2003.
Colonna, M. TREMs in the immune system and beyond. Nat. Rev. Immunol. 3: 445, 2003.
Ernst, T., Hergenhahn, M., Kenzelmann, M., et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: A gene expression analysis on total and microdissected prostate tissue. Am. J. Pathol. 160: 2169, 2002.
Genini, M., Schwalbe, P., Scholl, F. A., et al. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int. J. Cancer 66: 571, 1996.
Goldberg, S. F., Miele, M. E., Hatta, N., et al. Melanoma metastasis suppression by chromosome 6: Evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res. 63: 432, 2003.
Hill, C., Flyvbjerg, A., Gronbaek, H., et al. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 141: 1196, 2000.
Hill, C., Flyvbjerg, A., Rasch, R., et al. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J. Endocrinol. 170: 647, 2001.
Humtsoe, J. O., Feng, S., Thakker, G. D., et al. Regulation of cell-cell interactions by phosphatidic acid phosphatase 2b/VCIP. EMBO J. 22: 1539, 2003.
Kawaguchi, N., Sundberg, C., Kveiborg, M., et al. ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J. Cell Sci. 116: 3893, 2003.
Peters, D. G., Kassam, A. B., Feingold, E., et al. Molecular anatomy of an intracranial aneurysm: Coordinated expression of genes involved in wound healing and tissue remodeling. Stroke 32: 1036, 2001.
Pratta, M. A., Yao, W., Decicco, C., et al. Aggrecan protects cartilage collagen from proteolytic cleavage. J. Biol. Chem. 278: 45539, 2003.
Rigato, F., Garwood, J., Calco, V., et al. Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. J. Neurosci. 22: 6596, 2002.
Takeda, U., Utani, A., Wu, J., et al. Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J. Invest. Dermatol. 119: 678, 2002.
Trougakos, I. P., and Gonos, E. S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 34: 1430, 2002.
Tuxhorn, J. A., Ayala, G. E., Smith, M. J., et al. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8: 2912, 2002.
Wang, Y., De Keulenaer, G. W., Weinberg, E. O., et al. Direct biomechanical induction of endogenous calcineurin inhibitor Down syndrome critical region-1 in cardiac myocytes. Am. J. Physiol. 283: H533, 2002.
Chiu, H. F., and McFarlane, R. M. Pathogenesis of Dupuytren’s contracture: A correlative clinical-pathological study. J. Hand Surg. (Am.) 3: 1, 1978.
Luck, J. V. Dupuytren’s contracture: A new concept of the pathogenesis correlated with surgical management. J. Bone Joint Surg. (Am.) 41: 635, 1959.
Brickley-Parsons, D., Glimcher, M. J., Smith, R. J., et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren’s disease. J. Bone Joint Surg. (Am.) 63: 787, 1981.
Tomasek, J. J., Schultz, R. J., Episalla, C. W., et al. The cytoskeleton and extracellular matrix of the Dupuytren’s disease “myofibroblast”: An immunofluorescence study of a nonmuscle cell type. J. Hand Surg. (Am.) 11: 365, 1986.
Schultz, R. J., and Tomasek, J. J. Cellular structure and interconnections. In R. M. McFarlane, D. A. McGrouther, and M. Flint (Eds.), Dupuytren’s Disease Biology and Treatment. Edinburgh: Churchill Livingstone, 1990. Pp. 86–92.
Murrell, G. A., Francis, M. J., and Bromley, L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 265: 659, 1990.
Badalamente, M. A., Sampson, S. P., Hurst, L. C., et al. The role of transforming growth factor beta in Dupuytren’s disease. J. Hand Surg. (Am.) 21: 210, 1996.
Halliday, N. L., and Tomasek, J. J. Mechanical properties of the extracellular matrix influence fibronectin fibril assembly in vitro. Exp. Cell Res. 217: 109, 1995.
Hindman, H. B., Marty-Roix, R., Tang, J. B., et al. Regulation of expression of alpha-smooth muscle actin in cells of Dupuytren’s contracture. J. Bone Joint Surg. (Br.) 85: 448, 2003.
Pagnotta, A., Specchia, N., and Greco, F. Androgen receptors in Dupuytren’s contracture. J. Orthop. Res. 20: 163, 2002.
Pagnotta, A., Specchia, N., Soccetti, A., et al. Responsiveness of Dupuytren’s disease fibroblasts to 5 alpha-dihydrotestosterone. J. Hand Surg. (Am.) 28: 1029, 2003.
Starkweather, K. D., Lattuga, S., Hurst, L. C., et al. Collagenase in the treatment of Dupuytren’s disease: An in vitro study. J. Hand Surg. (Am.) 21: 490, 1996.
Badalamente, M. A., Hurst, L. C., and Hentz, V. R. Collagen as a clinical target: Nonoperative treatment of Dupuytren’s disease. J. Hand Surg. (Am.) 27: 788, 2002.